Mod­er­na goes af­ter Al­ny­lam, fil­ing coun­ter­claims in Spike­vax patent suit

Mod­er­na has gone on the of­fen­sive in its patent feud against Al­ny­lam, fil­ing two coun­ter­claims against the RNAi drug de­vel­op­er af­ter Al­ny­lam’s patent suit.

The two 44-page doc­u­ments, filed last Wednes­day in Delaware dis­trict court, ac­cus­es Al­ny­lam of “base­less­ly” look­ing to prof­it off Mod­er­na’s mul­ti-bil­lion-dol­lar block­buster Covid-19 vac­cine and asked the court to de­clare Al­ny­lam’s patent in­valid. Mod­er­na al­so said Al­ny­lam has no claim against Mod­er­na “to the ex­tent Mod­er­na used or man­u­fac­tured Spike­vax for the Gov­ern­ment and ‘with the au­tho­riza­tion or con­sent of the Gov­ern­ment’ un­der 28 U.S.C. § 1498.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN